Pfizer said in 2023 that it would dump a twice-daily version of danuglipron that moved to the middle stages of testing after multiple patients in a clinical trial stopped using the pill.

Pfizer said on Monday it has discontinued development of experimental weight-loss pill danuglipron after a trial patient experienced potential drug-induced liver injury that resolved after the ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and most expensive level of clinical testing.

Events Home 2025 Events Calendar Upcoming Events Brand Insider Summit Pharma & Health July 21 - 24, 2025, The Poconos Brand Insider Summit Retail August 17 - 20, 2025, Lake Tahoe ...

Pfizer stock (NYSE: PFE) was up 5% on Tuesday, December 17, after the company announced an optimistic outlook for 2025. The company expects its revenue to be in the range of $61 billion to $64 ...

Pfizer (PFE) is exploring the sale of its hospital drugs unit, now called Pfizer Hospital, which was formed after Pfizer bought Hospira for about $17B in 2015, three people familiar with the ...

Pfizer (NYSE: PFE) is scheduled to report its Q3 2024 results on Tuesday, October 29. We expect the company to post revenue of $15.1 billion and earnings of $0.63 on a per share and adjusted basis ...

FILE - The Pfizer logo is displayed at the company's headquarters, Friday, Feb. 5, 2021, in New York. Pfizer shares sank Friday, Dec. 1, 2023, when the drugmaker announced that it was abandoning a ...

Pfizer shares sank Friday when the drugmaker announced that it was abandoning a twice-daily obesity treatment after more than half the patients in a clinical trial stopped taking it.

FILE - The Pfizer logo is displayed at the company's headquarters, Friday, Feb. 5, 2021, in New York. Shares of Pfizer are falling before the market opened on Monday, Oct. 16, 2023, as the company ...